

PRESS RELEASE

29 June 2015

Recipharm appoints new Sales Director, Development Services

Recipharm, the leading contract development and manufacturing organization, is pleased to announce that Amine Tahiri has joined the Development Services Sales team in the role of Sales Director for France with effect from 1 July 2015. This appointment forms part of Recipharm's strategic drive to increase the volume of its business and revenues in key European markets.

Amine has more than 16 years experience from the pharmaceutical industry. Most recently Amine was Commercial Manager at Recipharm Fontaine S.A.S. He has also held managerial positions at Bristol-Myers Squibb, Laboratories Fournier and Solvay Pharmaceuticals. Amine is Doctor in Pharmacy from University of Pharmacy in Montpellier and holds an MBA from Dijon Business School.

Commenting on the new appointment, Torkel Gren, Senior Sales Director, Development Services at Recipharm, remarked: "I am very happy to welcome such a talent in the sales organisation. Amine will help in to increase our development business in France. We are looking forward to building new relationships with French companies in need of qualified pharmaceutical product development services".

Contact information

Torkel Gren, Senior Sales Director, Development Services, torkel.gren@recipharm.com, telephone: +46 8 602 45 60

Amine Tahiri, Sales Director, Development Services, amine.tahiri@recipharm.com, telephone: + 33 6 30 886 992

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: t.jervis@defacto.com or a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm's turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com